Eiger Has Positive Data For Its COVID-19 Drug, But Faces Uncertain Market

Peginterferon lambda helped reduce hospitalizations and deaths among high-risk COVID-19 patients in a Phase III trial.

3D_Coronavirus
Eiger announced data from its Phase III trial of peginterferon lambda in non-hospitalized COVID-19 patients. • Source: Shutterstock

Data from Eiger BioPharmaceuticals, Inc.’s Phase III TOGETHER study of peginterferon lambda in non-hospitalized COVID-19 patients at high risk of progressing to severe disease or death showed the subcutaneous drug as highly effective in preventing hospitalization and death.

The company plans to speak with the US Food and Drug Administration and submit for emergency use authorization, as well as seek authorization with other regulatory agencies, “as soon as possible

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from COVID-19

More from Scrip

In Brief: Positive New Data For Aptose’s Triplet Therapy In 1L AML

 

Aptose’s tuspetinib triplet shows early mutation-agnostic promise in new data from Phase I/II program for frontline acute myeloid leukemia.

Chinese Firms Build Obesity Clinical Pipeline But Face Wider Hurdles

 
• By 

Despite the ability to initiate clinical trials quickly and having strong manufacturing capacity, Chinese companies are facing multiple challenges in the obesity space.

Quick Listen: Scrip’s Five Must-Know Things

 
• By 

In this week's episode: AstraZeneca CEO cautions Europe; Pfizer CEO optimistic on US tariffs, pricing; Merck & Co reassures on pipeline; Merck KGaA buys SpringWorks; and Akeso explains ivonescimab overall survival data.